ID26334A - Morfolinol yang aktif secara farmasi - Google Patents

Morfolinol yang aktif secara farmasi

Info

Publication number
ID26334A
ID26334A IDW20001597A ID20001597A ID26334A ID 26334 A ID26334 A ID 26334A ID W20001597 A IDW20001597 A ID W20001597A ID 20001597 A ID20001597 A ID 20001597A ID 26334 A ID26334 A ID 26334A
Authority
ID
Indonesia
Prior art keywords
morpholinol
activate
pharmaceutical
pharmaceutical activate
activate morpholinol
Prior art date
Application number
IDW20001597A
Other languages
English (en)
Indonesian (id)
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partridge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ID26334A publication Critical patent/ID26334A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20001597A 1998-01-21 1999-01-20 Morfolinol yang aktif secara farmasi ID26334A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22

Publications (1)

Publication Number Publication Date
ID26334A true ID26334A (id) 2000-12-14

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001597A ID26334A (id) 1998-01-21 1999-01-20 Morfolinol yang aktif secara farmasi

Country Status (30)

Country Link
US (2) US6274579B1 (cg-RX-API-DMAC7.html)
EP (2) EP1047428B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002501025A (cg-RX-API-DMAC7.html)
KR (1) KR100568063B1 (cg-RX-API-DMAC7.html)
CN (2) CN1255389C (cg-RX-API-DMAC7.html)
AP (1) AP1229A (cg-RX-API-DMAC7.html)
AT (1) ATE365042T1 (cg-RX-API-DMAC7.html)
AU (1) AU755536B2 (cg-RX-API-DMAC7.html)
BR (1) BR9907203A (cg-RX-API-DMAC7.html)
CA (1) CA2318268A1 (cg-RX-API-DMAC7.html)
CY (1) CY1106828T1 (cg-RX-API-DMAC7.html)
DE (1) DE69936335T2 (cg-RX-API-DMAC7.html)
DK (1) DK1047428T3 (cg-RX-API-DMAC7.html)
EA (1) EA002410B1 (cg-RX-API-DMAC7.html)
EE (1) EE04452B1 (cg-RX-API-DMAC7.html)
ES (1) ES2288012T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20051024A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0100900A3 (cg-RX-API-DMAC7.html)
ID (1) ID26334A (cg-RX-API-DMAC7.html)
IL (2) IL161942A0 (cg-RX-API-DMAC7.html)
IS (1) IS2494B (cg-RX-API-DMAC7.html)
NO (2) NO326878B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ520349A (cg-RX-API-DMAC7.html)
PL (1) PL193622B1 (cg-RX-API-DMAC7.html)
PT (1) PT1047428E (cg-RX-API-DMAC7.html)
SG (1) SG115489A1 (cg-RX-API-DMAC7.html)
SK (1) SK10912000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200002126T2 (cg-RX-API-DMAC7.html)
WO (1) WO1999037305A1 (cg-RX-API-DMAC7.html)
YU (1) YU67102A (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
AU2349999A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US7145649B2 (en) * 2000-12-21 2006-12-05 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
KR20110043664A (ko) * 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
AU2003269923A1 (en) * 2002-08-23 2004-03-11 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
EP1678152A1 (en) * 2003-10-27 2006-07-12 Smithkline Beecham Corporation Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
US7763612B2 (en) * 2006-01-03 2010-07-27 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
WO2010121022A1 (en) 2009-04-15 2010-10-21 Research Triangle Institute Monoamine reuptake inhibitors
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
ES2687095T3 (es) 2010-05-21 2018-10-23 Research Triangle Institute Fenilimorfolinas y análogos de las mismas
EP2571859B1 (en) * 2010-05-21 2015-07-22 Research Triangle Institute 1-phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-(2-芳基吗啉-4-基)乙酯作为制备抗抑郁药物的应用
PE20150358A1 (es) 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
US6391875B2 (en) 2002-05-21
NO20003721D0 (no) 2000-07-20
PL193622B1 (pl) 2007-02-28
DE69936335D1 (de) 2007-08-02
EP1047428A1 (en) 2000-11-02
EP1047428B1 (en) 2007-06-20
EP1047428A4 (en) 2001-12-19
EA002410B1 (ru) 2002-04-25
NO326878B1 (no) 2009-03-09
NZ505809A (en) 2002-09-27
CY1106828T1 (el) 2012-05-23
HRP20000494A2 (en) 2000-12-31
HUP0100900A3 (en) 2002-08-28
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
AU2328099A (en) 1999-08-09
NO20083529L (no) 2000-09-19
BR9907203A (pt) 2000-10-17
AP2000001869A0 (en) 2000-09-30
EP1829544A1 (en) 2007-09-05
WO1999037305A1 (en) 1999-07-29
HRP20000494B1 (en) 2009-02-28
PT1047428E (pt) 2007-09-07
AP1229A (en) 2003-12-04
NO20003721L (no) 2000-09-19
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
SG115489A1 (en) 2005-10-28
ATE365042T1 (de) 2007-07-15
NZ520349A (en) 2004-02-27
US6274579B1 (en) 2001-08-14
CN1255389C (zh) 2006-05-10
IL161942A0 (en) 2005-11-20
EE04452B1 (et) 2005-04-15
EE200000438A (et) 2001-12-17
PL342012A1 (en) 2001-05-07
US20020019396A1 (en) 2002-02-14
DE69936335T2 (de) 2008-02-28
IS5568A (is) 2000-07-20
HRP20051024A2 (hr) 2006-04-30
AU755536B2 (en) 2002-12-12
HUP0100900A2 (hu) 2002-05-29
TR200002126T2 (tr) 2000-12-21
SK10912000A3 (sk) 2001-04-09
CN1294513A (zh) 2001-05-09
DK1047428T3 (da) 2007-10-08
EA200000691A1 (ru) 2001-04-23
KR20010034285A (ko) 2001-04-25
JP2002501025A (ja) 2002-01-15
KR100568063B1 (ko) 2006-04-07
ES2288012T3 (es) 2007-12-16
CN1203858C (zh) 2005-06-01
YU67102A (sh) 2004-12-31
NZ529316A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
ID26334A (id) Morfolinol yang aktif secara farmasi
ID28110A (id) Surfaktan alkilbenzenasulfonat yang disempurnakan
ID27841A (id) Turunan-turunan biaril terapeutik
IS5425A (is) Læknislyf
NO992339L (no) Farmasöytiske formuleringer
DE69924365D1 (de) Massagegerät
ID26330A (id) Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi
ID27415A (id) Komposisi farmaseutik
ID22939A (id) Formulasi-formulasi farmasi yang mengandung vorikonozal
NO992692D0 (no) Nefadozon doseringsform
ID29262A (id) Komposisi farmasi
DK1466615T3 (da) Farmaceutisk præparat
DE69921571D1 (de) Massagegerät
ID23735A (id) Tablet trovafloksasin mesilat
DE69908262D1 (de) Sprühbehälter
ID27201A (id) Komposisi farmasi
EP1061784A4 (en) RADIO-ELECTRONIC UNIT
NO994619L (no) Farmasöytiske blandinger
ID30032A (id) Formulasi farmasi
EP1074250A4 (en) SUGAR-COATED TABLETS
FR2782671B3 (fr) Livre
NO20003141D0 (no) Farmasøytiske blandinger
DK1051156T3 (da) Farmaceutiske præparater
DE59904743D1 (de) Exzenteranordnung
ID27593A (id) Tetrahidronaftilidinil-karboksamida yang mempunyai aktivitas anti-konvulsan